Cite
HARVARD Citation
Tanaka, Y. et al. (n.d.). FRI0251 SIRUKUMAB, an ANTI-IL-6 cytokine monoclonal antibody, leads to improvements in work productivity and general health status in patients with active rheumatoid arthritis refractory to ANTI-TNF therapy: results from the phase 3 SIRROUND-T study. Annals of the rheumatic diseases. p. 580. [Online].